Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary $beta;-radiation therapy

Radke, Peter W.; Kobella, Stefan; Kaiser, Axel; Franke, Andreas; Schubert, D; Grube, Eberhard; Hanrath, Peter; Hoffmann, Rainer

doi:10.1016/j.ehj.2004.02.014

Cited by 44 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary observational studies have demonstrated encouraging results with the use of these new stents in patients with ISR (11)(12)(13)(14). Moreover, recent studies suggest that drug-eluting stents might even be superior to brachytherapy which, up to now, constitutes the only proven effective therapy in this challenging scenario (15)(16)(17).…”

Section: See Page 2161mentioning

confidence: 99%

A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis

Alfonso

Pérez-Vizcayno

Hernández

et al. 2006

Journal of the American College of Cardiology

149

View full text Add to dashboard Cite

show abstract

Section: See Page 2161mentioning

confidence: 99%

A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis

Alfonso

Pérez-Vizcayno

Hernández

et al. 2006

Journal of the American College of Cardiology

149

View full text Add to dashboard Cite

show abstract

“…At 6 months, the restenosis rate was 20% in the PES group and 16% in the brachytherapy group (P = 1.0), but PES implantation resulted in significantly larger in-stent MLD (P = 0.03) and in-stent net gain (P = 0.04). TLR at 12 months was not significantly different between the two treatment groups [31]. Another comparative study came from the Netherlands.…”

Section: In-stent Restenosismentioning

confidence: 94%

Contemporary use of drug-eluting stents

Chu¹,

Waksman

2005

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Since the era of balloon angioplasty, stents have been a revolutionary advance in the treatment of severe coronary artery disease. However, one of the major limitations is in-stent restenosis. Although brachytherapy was found to be an effective treatment, the goal remains to develop a kind of stent that will not restenose. The emergence of drug-eluting stents provided a novel solution for the reduction of restenosis. The currently approved indication for drug-eluting stents by the US Food and Drug Administration is for discrete, de novo lesions in native vessels with reference vessel diameters of 2.5 to 3.5 mm. However, in the worldwide daily practice, there have been numerous off-label uses of drug-eluting stents, and their long-term follow-up and experience in more complex lesions are accumulating. This article reviews the current off-label uses of drug-eluting stents. The majority of the supporting data are from registry and observational studies, yet many studies are limited by small sample sizes. Therefore, large, prospective, randomized, double-blind, and controlled trials are definitely warranted to further support current practice. Nevertheless, the "real world" unrestricted uses of drug-eluting stents seem to be the current trend in the interventional field.

show abstract

“…Similarly, Paclitaxel possesses strong cytotoxicity and poor selectivity, so it inhibits the proliferation of smooth MCs and hurts normal cells at the same time, which may bring about distal stimulating effect and cause long-term restenosis, explaining the fact of 20% restenosis in 6 months. [3][4][5][6][7] In 2005, Aoki J from Toronto University reported that the third generation bioengineered stent captures cells in peripheral blood and accelerates natural repair of blood vessels by loading antibody in the coating. The CD34 stent was developed with CD34 antibody fixed by Teflon on the surface, and it accelerates endothelialization of blood vessels by capturing endothelial progenitor cells (EPCs) in peripheral blood to injured regions.…”

Section: Introductionmentioning

confidence: 99%

Hematopoietic Stem Cell Capture and Directional Differentiation into Vascular Endothelial Cells for Metal Stent-Coated Chitosan/Hyaluronic Acid Loading CD133 Antibody

Zhang

Zhang²,

Feng³

et al. 2015

Tissue Engineering Part A

View full text Add to dashboard Cite

A series of metal stents coated with chitosan/hyaluronic acid (CS/HA) loading antibodies by electrostatic selfassembled method were prepared, and the types of cells captured by antibodies and their differentiation in vascular endothelial cells (ECs) evaluated by molecular biology and scanning electron microscope. The results showed that CD133 stent can selectively capture hematopoietic stem cells (HSC),which directionally differentiate into vascular ECs in peripheral blood by (CS/HA) induction, and simultaneously inhibit migration and proliferation of immune cells and vascular smooth muscle cells (MCs). CD34 stent can capture HSC, hematopoietic progenitor cells that differentiate into vascular ECs and immune cells, promoting smooth MCs growth, leading to thrombosis, inflammation, and rejection. CD133 stent can be implanted into miniature pig heart coronary and can repair vascular damage by capturing own HSC, thus contributing to the rapid natural vascular repair, avoiding inflammation and rejection, thrombosis and restenosis. These studies demonstrated that CD133 stent of HSC capture will be an ideal coated metal stent providing a new therapeutic approach for cardiovascular and cerebrovascular disease.

show abstract

Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary $beta;-radiation therapy

Abstract: Implantation of a non-polymer based paclitaxel-elution stent and conventional ICR therapy for complex ISR lead to comparable acute and long-term clinical and angiographic follow-up results.

Cited by 44 publications

References 20 publications

A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis

A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis

Contemporary use of drug-eluting stents

Hematopoietic Stem Cell Capture and Directional Differentiation into Vascular Endothelial Cells for Metal Stent-Coated Chitosan/Hyaluronic Acid Loading CD133 Antibody

Contact Info

Product

Resources

About